Juvenile idiopathic arthritis articles from across Nature Portfolio

Juvenile idiopathic arthritis treatment has evolved with new therapies, early remission goals and global efforts, including randomized trials and a treat-to-target strategy. This Review summarizes current evidence and therapeutic approaches to the management of non-systemic phenotypes of juvenile idiopathic arthritis.

Treatment of ‘classic’ systemic juvenile idiopathic arthritis (sJIA) is evolving markedly, and treatment options for early sJIA without arthritis, and refractory or complicated sJIA are not well defined. This Review outlines current approaches and provides an outlook on knowledge gaps.

In this Review, the authors discuss age-related arthropathy and the similarities and differences between childhood loss of immune tolerance and adult development of immune-mediated arthritis, and develop three hypotheses describing age-related mechanisms that contribute to the onset of arthritis.

This Primer by Martini and colleagues summarizes the epidemiology, pathophysiology, diagnosis and management of Juvenile idiopathic arthritis (JIA), the most common chronic inflammatory rheumatic condition of childhood. In addition, this Primer discusses the quality of life of children with JIA and reviews future research directions to improve patient care.

New findings support the use of targeted next-generation sequencing of NOD2 to reassess the diagnosis of juvenile idiopathic arthritis in patients with signs and symptoms suggestive of Blau syndrome.

In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.

Phase II trial results demonstrate rapid remission of macrophage activation syndrome in patients treated with the anti-IFNγ antibody emapalumab.

New evidence from animal models and human studies suggests that mammalian target of rapamycin has a role in the pathophysiology of Still’s disease and macrophage activation syndrome.

Transitional care in rheumatology has been debated for over three decades and yet unmet needs of young people are still being reported. Why the slow progress? Perhaps we need to stop talking about transitional care in rheumatology and talk more about developmentally appropriate health care for young people with rheumatic conditions.

Oral tofacitinib led to fewer flares in patients with juvenile idiopathic arthritis than placebo, according to the results of a phase III trial.